Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006

HIV Medicine

Volumn 8, Issue 6, 2007, Pages 367-373

  Smyth, K ^a,b   Affandi, J S ^c   Mcarthur, J C ^d   Bowtell harris, C ^e   Mijch, A M ^e,f   Watson, K ^e   Costello, K ^e   Woolley, I J ^e,f   Price, P ^g   Wesselingh, S L ^b,e,f   Cherry, Catherine L ^b,e,f  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e ALFRED HOSPITAL   (Australia)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

HIV associated neuropathy; Nucleoside reverse transcriptase inhibitor; Protease inhibitor; Risk factor; Stavudine

Indexed keywords

DIDANOSINE; INDINAVIR; STAVUDINE; ZALCITABINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; DEMOGRAPHY; DRUG EXPOSURE; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SENSORY NEUROPATHY; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; POLYNEUROPATHIES; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; STAVUDINE;

EID: 34547459450     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00478.x     Document Type: Article

References (29)

1. Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS 2002; 16: 2105-2117.
2. So Y, Holtzman D, Abrams D, Olney R. Peripheral neuropathy associated with acquired immunodeficiency syndrome - prevalence and clinical features from a population-based survey. Arch Neurol 1988; 45: 945-948.
3. Cornblath D, McArthur J. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38: 794-796.
4. de la Monte S, Gabuzda D, Ho D et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988; 23: 485-492.
5. Norton G, Sweeney J, Marriott D, Law M, Brew B. Association between HIV distal symmetric polyneuropathy and Mycobacterium avium complex infection. J Neurol Neurosurg Psychiatry 1996; 61: 606-609.
6. Barohn R, Gronseth G, LeForce B et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993; 50: 167-170.
7. Woolley I, Faragher M, Ugoni A, Spelman D. An analysis of factors associated with HIV-related peripheral neuropathy. Neurol Infect Epidemiol 1997; 2: 33-37.
8. Childs E, Lyles R, Selnes OBC et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607-613.
9. Yarchoan R, Perno C, Thomas R et al. Phase 1 studies of 2′, 3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76-81.
10. Lambert J, Seidlin M, Reichmann R et al. 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990; 322: 1333-1340.
11. Browne M, Mayer K, Chafee S et al. 2′, 3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial. J Infect Dis 1993; 167: 21-29.
12. Bacellar H, Munoz A, Miller E et al. Temporal trends in the incidence of HIV-1-related neurologic diseases. Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994; 44: 1892-1900.
13. Pettersen J, Jones G, Worthington C et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006; 59: 816-824.
14. Watters M, Poff P, Shiramizu B et al. Symptomatic distal sensory polyneuropathy in HIV after age 50. Neurology 2004; 62: 1378-1383.
15. Morgello S, Estanislao L, Simpson D et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy. The Manhattan HIV Brain Bank. Arch Neurol 2004; 61: 546-551.
16. Cherry C, Skolasky R, Lal L et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006; 66: 867-873.
17. Lichtenstein K, Armon C, Baron A et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40: 148-157.
18. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexual transmissible infections in Australia Annual Surveillance Report 2005. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney; Australian Institute of Health and Welfare, Canberra http://web.med.unsw.edu.au/ nchecr/surv_anrep.html 2005.
19. Cherry C, McArthur J, Costello K, Woolley I, Mijch A, Wesselingh S. Increasing prevalence of neuropathy in the era of highly active antiretroviral therapy (HAART). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 2002 [Abstract 69].
20. Cherry C, Wesselingh S, Lal L, McArthur J. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology 2005; 65: 1778-1781.
21. Dore G, Li Y, McDonald A, Ree H, Kaldor J. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. National HIV Surveillance Committee. J Acquir Immune Defic Syndr 2002; 29: 388-395.
22. Dore G, Correll P, Li Y, Kaldor J, Cooper D, Brew B. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13: 1249-1253.
23. Winston A, McAllister J, Amin J, Cooper D, Carr A. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med 2005; 6: 191-197.
24. Keswani S, Polley M, Pardo C, Griffin J, McArthur J, Hoke A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003; 54: 287-296.
25. Forma F, Liechty C, Selberg P et al. Early clinical toxicity to nonnucleoside reverse transcriptase inhibitor-based HAART in a home-based AIDS care program in rural Uganda. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 142].
26. Kim A, Ngan'ga L, Macharia D et al. Adverse events in HIV-infected patients receiving ART in a treatment program in a Nairobi slum, Kenya, 2003-05. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Abstract 143].
27. Enting R, Hoetelmans R, Lange J, Burger D, Beijnen J, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12: 1941-1955.
28. Capparelli E, Holland D, Okamoto C et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 2005; 19: 949-952.
29. Brambilla A, Novati R, Calori G et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17: 1993-1995.